Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models

Vasilios Liapis(Basil Hetzel Institute), Andreas Evdokiou(Royal Adelaide Hospital)
Cancer Medicine
January 9, 2016
Cited by 30


Related Papers